Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

It is time for those working on oncolytic viruses to take stock of the status of the field. We now have at our disposal an array of potential therapeutic agents, and are beginning to conduct early-phase clinical trials in patients with relapsed/metastatic cancers. By drawing on lessons learned during the development of other biological therapies, such as monoclonal antibodies and targeted small molecule inhibitors, we are now in a position to chart the course of the next wave of trials that will go beyond the phase I studies of safety and feasibility. In this article we review our approach to the development of oncolytic viruses as cancer therapeutics. In doing so, we emphasise the fact that this process is modular and involves multiple iterative steps between the laboratory and the clinic. Ultimately, at least in the medium term, the future of oncolytic virotherapy lies in combination regimens with standard anti-cancer agents such as radiation and chemotherapy.

• Publication year

  2010

• Venue

  Cytokine & growth factor reviews

• Publication date

  2010-03-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cytogfr.2010.02.006PMID 20223697PMCID 3915505
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

  2010cited by this paper
• HPMA copolymers for masking and retargeting of therapeutic viruses.

  2010cited by this paper
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

  2010cited by this paper
• Intelligent Design: Combination Therapy With Oncolytic Viruses.

  2010cited by this paper
• Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma

  2009cited by this paper
• The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon

  2009cited by this paper
• Recent Advances Relating to the Clinical Application of Naked Monoclonal Antibodies in Solid Tumors

  2009cited by this paper
• Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

  2009cited by this paper
• As nature intended

  2009cited by this paper
• A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

  2008cited by this paper
• A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting

  2008cited by this paper
• Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

  2008cited by this paper
• Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

  2008cited by this paper
• Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

  2008cited by this paper
• Virus combinations and chemotherapy for the treatment of human cancers.

  2008cited by this paper
• A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

  2008cited by this paper
• Reovirus: viral therapy for cancer 'as nature intended'.

  2008cited by this paper
• Exploiting synergies between radiation and oncolytic viruses.

  2008cited by this paper
• Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

  2008cited by this paper
• In situ Activation of Dendritic Cells (DC) with Imiquimod for Cancer Immunotherapy

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• The preferential cytotoxicity of reovirus for certain transformed cell lines

  2005cited by this paper
• Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.

  2005cited by this paper
• Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

  2005cited by this paper
• Prevalence of Reovirus-Specific Antibodies in Young Children in Nashville, Tennessee

  2005cited by this paper
• Genetically Targeted Cancer Therapy

  2004cited by this paper
• Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2.

  2004cited by this paper
• Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts.

  2003cited by this paper
• Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery?

  2002cited by this paper
• A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

  2000cited by this paper
• Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

  1999cited by this paper
• The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

  1998cited by this paper
• Reovirus therapy of tumors with activated Ras pathway.

  1998cited by this paper
• The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection

  1996cited by this paper
• Recent developments in radioimmunotherapy.

  1994cited by this paper
• A phase‐i study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin a to suppress the immune response

  1991cited by this paper
• Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.

  1990cited by this paper
• Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon

  1990cited by this paper
• ras oncogenes in human cancer: a review.

  1989influential reference
• Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.

  1988cited by this paper
• Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms.

  1986cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984influential reference
• Protamine precipitation of two reovirus particle types from polluted waters

  1982cited by this paper
• Evaluation of cell lines and immunofluorescence and plaque assay procedures for quantifying reoviruses in sewage

  1982cited by this paper
• IgM antibodies induce the production of antibodies of the same specificity.

  1980cited by this paper
• Continuous cultures of fused cells secreting antibody of predefined specificity

  1975cited by this paper
• Reovirus infections in human volunteers.

  1963cited by this paper
• Observations on a newly recognized virus (Abney) of the reovirus family.

  1960cited by this paper

• Reovirus oncolysis and the next frontiers for this unique oncoviral immunotherapy.

  2025cites this paper
• Oncolytic viruses in cancer therapy: Exploring the mechanisms and clinical potential of mammalian and avian reoviruses

  2025cites this paper
• Oncolytic Reovirus-Induced Prostaglandin E2 Production in Human Tumor Cells.

  2025cites this paper
• Frontier knowledge and future directions of programmed cell death in clear cell renal cell carcinoma

  2024cites this paper
• Neutrophils in oncolytic virus immunotherapy

  2024cites this paper
• Molecular insights and promise of oncolytic virus based immunotherapy.

  2024cites this paper
• Oncolytic viruses against cancer, promising or delusion?

  2023cites this paper
• Therapy with oncolytic viruses: progress and challenges

  2023cites this paper
• Involvement of Protein Kinase R in Double-Stranded RNA-Induced Proteasomal Degradation of Hypoxia Inducible Factor-1α

  2023cites this paper
• Modulation of Reoviral Cytolysis (II): Cellular Stemness

  2023cites this paper
• Emulating interactions between microorganisms and tumor microenvironment to develop cancer theranostics

  2022cites this paper
• Oncolytic viruses in immunotherapy

  2022cites this paper
• Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions

  2022cites this paper
• A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner

  2021cites this paper
• Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer

  2021cites this paper
• A bibliometric review of oncolytic virus research as a novel approach for cancer therapy

  2021cites this paper
• MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice

  2021cites this paper
• Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

  2021cites this paper
• The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?

  2020cites this paper
• Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

  2020cites this paper
• The Good, the Bad and the Tick

  2019cites this paper
• Sialic Acids in Nonenveloped Virus Infections.

  2019cites this paper
• The emerging role of oncolytic virus therapy against cancer.

  2018cites this paper
• Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses

  2018cites this paper
• Designer Oncolytic Adenovirus: Coming of Age

  2018cites this paper
• Multiple proteins differing between laboratory stocks of mammalian orthoreoviruses affect both virus sensitivity to interferon and induction of interferon production during infection.

  2018cites this paper
• Oncolytic Viruses and Its Commercialization A mini review

  2016cites this paper
• Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release

  2016cites this paper
• Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models

  2016cites this paper
• Experimental Adaptation of Rotaviruses to Tumor Cell Lines

  2016cites this paper
• Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling

  2016cites this paper
• Virus-Infected Human Mast Cells Enhance Natural Killer Cell Functions

  2016cites this paper
• Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma

  2016cites this paper
• Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

  2016cites this paper
• Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

  2016cites this paper
• Combinaison d’approches classiques et de génétique inverse en vue d'une meilleure compréhension du tropisme et de l'activité oncolytique du réovirus de mammifères

  2015influential citation
• Comparative proteomic analyses of two reovirus T3D subtypes and comparison to T1L identifies multiple novel proteins in key cellular pathogenic pathways

  2015cites this paper
• Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data

  2015cites this paper
• Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus.

  2015cites this paper
• Oncolytic viruses: From bench to bedside with a focus on safety

  2015cites this paper
• Gene Therapy and Virus-Based Cancer Vaccines

  2015cites this paper
• Amino acids substitutions in σ1 and μ1 outer capsid proteins of a Vero cell-adapted mammalian orthoreovirus are required for optimal virus binding and disassembly.

  2015cites this paper
• Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia

  2015cites this paper
• Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike

  2015cites this paper
• Gene Therapy of Solid Cancers

  2015cites this paper
• Chemovirotherapy : combining chemotherapeutic treatment with onco lytic virotherapy eike

  2015cites this paper
• Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy

  2015cites this paper
• Oncolytic Newcastle Disease Virus as treatment for pancreatic cancer

  2015cites this paper
• Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants

  2015cites this paper
• Oncolytic Viral Therapy Using Reovirus.

  2015cites this paper
• Radiovirotherapy for the Treatment of Cancer

  2014cites this paper
• Molecular effects of Mammalian Orthoreovirus (MRV) infection on hypoxic prostate tumor cells

  2014cites this paper
• Mammalian orthoreovirus T3D infects U-118 MG cell spheroids independent of junction adhesion molecule-A

  2014cites this paper
• Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells

  2014cites this paper
• Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

  2014cites this paper
• 8th International Conference on Oncolytic Virus Therapeutics

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

  2014cites this paper
• Enhanced susceptibility of B lymphoma cells to measles virus by Epstein–Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule

  2014cites this paper
• HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic Mammalian Orthoreovirus

  2014cites this paper
• The Progress of Oncolytic Reovirus in Hematologic Malignancies: Can We Combat Blood Cancer with the Cold?

  2014cites this paper
• Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cells

  2013cites this paper
• Transient high level mammalian reovirus replication in a bat epithelial cell line occurs without cytopathic effect.

  2013cites this paper
• Development of bacterial nitroreductase enzymes for noninvasive imaging in cancer gene therapy

  2013cites this paper
• Development of Oncolytic Reovirus for Cancer Therapy

  2013cites this paper
• Regulating cytokine function enhances safety and activity of genetic cancer therapies.

  2013cites this paper
• Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer

  2013cites this paper
• Amino acid substitutions in σ1 and μ1 outer capsid proteins are selected during mammalian reovirus adaptation to Vero cells.

  2013cites this paper
• Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis

  2013cites this paper
• Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies

  2012cites this paper
• Theranostic Potential of Oncolytic Vaccinia Virus

  2012cites this paper
• Addition of exogenous polypeptides on the mammalian reovirus outer capsid using reverse genetics.

  2012cites this paper
• Virotherapy--cancer targeted pharmacology.

  2012cites this paper
• Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients

  2012cites this paper
• The Hitchhiker's Guide to Virotherapy

  2012cites this paper
• Recent clinical experience with oncolytic viruses.

  2012cites this paper
• ONCOLYTIC VIROTHERAPY

  2012cites this paper
• Immune mediated and direct killing of colorectal cancer by reovirus

  2012cites this paper
• Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy

  2012cites this paper
• Étude de la protéine sigma 1 de réovirus par génétique inverse

  2012influential citation
• Clinical trials involving the oncolytic virus, reovirus: ready for prime time?

  2012cites this paper
• Adair Tumor in Patients Cell Carriage , Delivery , and Selective Replication of an Oncolytic Virus in

  2012cites this paper
• Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer

  2012cites this paper
• Reovirus: A Targeted Therapeutic—Progress And Potential

  2012cites this paper
• Quantification of the Host Response Proteome after Mammalian Reovirus T1L Infection

  2012cites this paper
• Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

  2012cites this paper
• Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma

  2012cites this paper
• Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

  2012cites this paper
• Cancer Therapy: Clinical A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

  2011cites this paper
• Oncolytic virotherapy for pancreatic cancer

  2011cites this paper
• High therapeutic potential for systemic delivery of a liposome-conjugated herpes simplex virus.

  2011cites this paper
• The impact of hypoxia on oncolytic virotherapy

  2011cites this paper
• Virus Adaptation and Treatment The impact of hypoxia on oncolytic virotherapy

  2011cites this paper
• Oncolytic virus-initiated protective immunity against prostate cancer.

  2011cites this paper
• Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer.

  2011cites this paper
• Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming

  2011cites this paper
• Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.

  2011cites this paper
• Phase I/II Study of Oncolytic HSV in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck

  2010cites this paper
• A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

  2010cites this paper
• REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

  2010cites this paper